{"gene":"ALDH1A3","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2000,"finding":"RALDH3 (ALDH1A3) functions as a retinaldehyde dehydrogenase, catalyzing the oxidation of retinaldehyde to retinoic acid, and is expressed specifically in the ventral retina, otic vesicle, and olfactory pit during mouse embryonic development, with expression pattern distinct from RALDH1 and RALDH2.","method":"cDNA cloning, in situ hybridization, expression pattern analysis in mouse embryos","journal":"Mechanisms of development","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic activity (retinaldehyde dehydrogenase) established by cloning and expression; replicated independently in two papers (PMID 11025231, PMID 11044606) with orthogonal methods including enzymatic activity assays","pmids":["11025231","11044606"],"is_preprint":false},{"year":1994,"finding":"ALDH6 (ALDH1A3) encodes a 512 amino acid aldehyde dehydrogenase isozyme expressed highly in salivary gland, stomach, and kidney, and maps to chromosome 15q26; the gene spans ~37 kb with 13 exons.","method":"cDNA cloning, Northern blot analysis, fluorescence in situ hybridization for chromosomal localization","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct molecular cloning with enzymatic classification, chromosomal mapping, and expression profiling; foundational characterization paper","pmids":["7698756"],"is_preprint":false},{"year":2000,"finding":"RALDH-3 (ALDH1A3) is the chick ortholog of human ALDH6, is specifically expressed in the ventral retina, and shows enzymatic activity to produce retinoic acid from retinaldehyde; its expression in the ventral retina is dependent on Pax6 transcription factor.","method":"Restriction landmark cDNA scanning, enzymatic activity assay, in situ hybridization, Pax6 mutant analysis","journal":"Mechanisms of development","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzymatic activity directly demonstrated in vitro; Pax6 dependency shown in mutant embryos; replicated across labs","pmids":["11044606"],"is_preprint":false},{"year":2006,"finding":"Raldh3 expression in the subventricular zone of the lateral ganglionic eminence (LGE) is required for retinoic acid signaling in the ventral forebrain; Raldh3 null mice lack RA signaling in the ventral forebrain and show essentially eliminated dopamine receptor D2 expression in the developing nucleus accumbens.","method":"Genetic epistasis using Raldh2/Raldh3 single and double null mouse mutants, RA signaling reporter assays, in situ hybridization","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function genetics with defined molecular and cellular phenotype; double-knockout epistasis; multiple orthogonal readouts","pmids":["17207476"],"is_preprint":false},{"year":2007,"finding":"ALDH1A3 is an androgen-responsive gene in prostate cancer LNCaP cells: dihydrotestosterone (DHT) induces a ~4-fold increase in ALDH1A3 mRNA via the androgen receptor (AR) nuclear-translocation cascade, and DHT-upregulated ALDH1A3 increases retinaldehyde-dependent NAD+ reduction ~8-fold, leading to increased retinoic acid biosynthesis.","method":"qRT-PCR, siRNA knockdown of AR, pharmacologic inhibition of AR (bicalutamide) and kinases (PD98059, PP1), enzymatic activity assay (retinaldehyde-dependent NAD+ reduction), CYP26A1 mRNA induction","journal":"Experimental biology and medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (siRNA, pharmacologic inhibitors, enzymatic assay) in single lab demonstrating AR-dependent transcriptional regulation and functional enzymatic consequence","pmids":["17526768"],"is_preprint":false},{"year":2011,"finding":"ALDH activity of breast cancer stem cells is primarily attributable to ALDH1A3 expression, not ALDH1A1; shRNA knockdown of ALDH1A3 (but not other isoforms) uniformly reduces ALDH activity in breast cancer cells.","method":"Genome microarray expression, immunofluorescence, qPCR, shRNA knockdown, Aldefluor assay","journal":"Stem cells (Dayton, Ohio)","confidence":"High","confidence_rationale":"Tier 2 / Strong — isoform-specific shRNA knockdown with direct functional readout (ALDH activity), replicated across multiple cell lines and patient tumor CSCs","pmids":["21280157"],"is_preprint":false},{"year":2013,"finding":"Loss-of-function mutations in ALDH1A3 cause autosomal recessive anophthalmia/microphthalmia in humans; missense mutations reduce accumulation of the enzyme, likely leading to altered retinoic acid synthesis during eye development.","method":"Homozygosity mapping, exome sequencing, Sanger sequencing, transitory expression of mutant ALDH1A3 ORFs to assess protein accumulation","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetics with functional validation of mutant protein expression; replicated in multiple independent families and studies (PMID 23312594, 23591992, 23646827, 23881059)","pmids":["23312594","23591992","23646827","23881059"],"is_preprint":false},{"year":2013,"finding":"Morpholino-mediated knockdown of aldh1a3 in zebrafish causes significant reduction in eye size and aberrant axonal projections to the tectum, confirming a conserved role in eye development.","method":"Antisense morpholino injection in Danio rerio, eye size measurement, axonal projection analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean loss-of-function in animal model with defined phenotype (eye size, axonal projections); single lab, single model organism","pmids":["23591992"],"is_preprint":false},{"year":2013,"finding":"A missense mutation (p.Val71Met) in ALDH1A3 associated with isolated anophthalmia/microphthalmia showed no change in enzymatic activity in vitro, suggesting the pathogenic mechanism may involve altered protein stability or localization rather than catalytic impairment.","method":"In vitro enzymatic activity assay of wild-type vs. mutant ALDH1A3 protein","journal":"European journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro enzymatic assay; single lab, negative finding (no activity change) that is mechanistically informative","pmids":["23881059"],"is_preprint":false},{"year":2015,"finding":"A pSTAT3(tyr705)-NFkB(p65) complex represses DDIT3 mRNA, which ensures high CEBPβ-dependent ALDH1A3 promoter activity; inhibition of this STAT3-NFkB axis allows DDIT3 expression, which forms a DDIT3-CEBPβ complex that reduces CEBPβ occupancy at the ALDH1A3 promoter, thereby reducing ALDH1A3 expression in chemoresistant mesothelioma cells.","method":"RNAi, promoter activity assays, ChIP, co-immunoprecipitation, in vivo xenograft models","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter occupancy by ChIP, co-IP of STAT3-NFkB complex, and RNAi loss-of-function; single lab with multiple orthogonal methods","pmids":["25868979"],"is_preprint":false},{"year":2016,"finding":"FOXD1 transcription factor directly regulates the transcriptional activity of ALDH1A3 in mesenchymal glioma stem cells (MES GSC); shRNA attenuation of FOXD1 ablates ALDH1A3-dependent clonogenicity in vitro and in vivo.","method":"shRNA knockdown, in vitro clonogenicity assays, in vivo xenograft models, RNAi in Drosophila brain tumor model (genetic conservation), luciferase reporter for ALDH1A3 transcription","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis demonstrated by shRNA knockdown of both genes with clonogenicity readout; FOXD1 regulation of ALDH1A3 transcription shown; single lab","pmids":["27569208"],"is_preprint":false},{"year":2016,"finding":"Sam68 (KHDRBS1) RNA-binding protein binds to an intronic polyadenylation site in Aldh1a3 pre-mRNA, preventing premature transcript termination and enabling expression of full-length functional ALDH1A3 enzyme; loss of Sam68 reduces ALDH1A3 expression and activity, leading to reduced glycolysis and clonogenicity in neural progenitor cells.","method":"Khdrbs1 knockout mouse, pre-mRNA 3'-end processing assay, clonogenicity, glycolysis assays, RNA-binding protein binding experiments","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with mechanistic dissection of RNA processing (intronic polyadenylation site binding), multiple functional readouts (glycolysis, clonogenicity, NPC pool), single rigorous study with orthogonal methods","pmids":["27845622"],"is_preprint":false},{"year":2017,"finding":"ALDH1A3 regulates transcriptional expression of tissue transglutaminase (tTG) via its retinoic acid (RA) biosynthesis activity in mesenchymal glioma stem cells; enzymatic activity of ALDH1A3 and its product RA are necessary for tTG expression, and ectopic ALDH1A3 expression in proneural GSCs is sufficient to induce tTG.","method":"shRNA/siRNA knockdown, ectopic ALDH1A3 expression, RA supplementation rescue experiments, inhibitor treatment","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with RA rescue; enzymatic activity linked to downstream effector (tTG); single lab, multiple orthogonal approaches","pmids":["28423611"],"is_preprint":false},{"year":2018,"finding":"CHD7 (an ATP-dependent chromatin remodeler) directly binds and represses the Aldh1a3 gene in the inner ear; loss of Aldh1a3 partially rescues Chd7 mutant mouse inner ear defects, placing CHD7 upstream of ALDH1A3 in a common genetic pathway regulating inner ear development.","method":"CHD7 chromatin binding assays, Chd7/Aldh1a3 double mutant genetic epistasis in mice, inner ear phenotypic rescue analysis","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct CHD7 binding to Aldh1a3 gene demonstrated; double-mutant genetic rescue epistasis in mouse; mechanistically rigorous single study","pmids":["29467333"],"is_preprint":false},{"year":2018,"finding":"ALDH1A3 protein is regulated post-translationally by autophagy: ALDH1A3 physically interacts with p62 (sequestosome 1/SQSTM1), an autophagosome adaptor protein, and temozolomide-induced autophagy leads to ALDH1A3 protein downregulation without affecting mRNA levels.","method":"Co-immunoprecipitation (ALDH1A3-p62 interaction), Western blot, qPCR (mRNA vs protein level comparison), autophagy induction/inhibition","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP demonstrating physical interaction with p62; mRNA vs protein discordance supporting post-transcriptional regulation; single lab","pmids":["29306018"],"is_preprint":false},{"year":2019,"finding":"USP9X (ubiquitin-specific protease 9X) acts as a bona fide deubiquitinase of ALDH1A3 in mesenchymal glioblastoma stem cells: USP9X interacts with ALDH1A3, depolyubiquitylates it, and stabilizes the protein; depletion of USP9X downregulates ALDH1A3, causing loss of self-renewal and tumorigenicity that can be rescued by ectopic ALDH1A3 expression.","method":"Co-immunoprecipitation, ubiquitination assays (depolyubiquitylation), USP9X depletion + ALDH1A3 rescue experiments, orthotopic xenograft models, USP9X inhibitor (WP1130) treatment","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, direct deubiquitination assay, epistatic rescue experiment, in vivo validation; multiple orthogonal methods in single rigorous study","pmids":["30958800"],"is_preprint":false},{"year":2019,"finding":"ALDH1A3 regulates expression of lncRNA NRAD1 through retinoic acid signaling; NRAD1 is primarily nuclear-localized and functions downstream of ALDH1A3 to regulate gene expression via chromatin interactions, mediating part of ALDH1A3's effects on cancer stem cell gene expression.","method":"Cellular fractionation (nuclear localization), transcriptome profiling, ChIRP-seq (chromatin isolation by RNA purification + sequencing), antisense oligonucleotide knockdown, ALDH1A3 knockdown with NRAD1 measurement","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular fractionation, ChIRP-seq for chromatin interactions, RA rescue experiments; single lab with multiple orthogonal methods","pmids":["31197235"],"is_preprint":false},{"year":2019,"finding":"ALDH1A3 promotes vascular smooth muscle cell (VSMC) proliferation at least partially through upregulation of matricellular proteins TNC1 and ESM1, which activate AKT/mTOR and/or MEK/ERK pathways; ALDH1A3 silencing abolishes PDGF(BB)-stimulated VSMC total ALDH activity and proliferation.","method":"siRNA knockdown, ALDH activity assay, proliferation assay, pathway inhibition, in vivo angioplasty rat carotid model with ALDH inhibitor disulfiram","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with defined cellular phenotype (proliferation), downstream effector identification (TNC1/ESM1), in vivo validation; single lab","pmids":["31513972"],"is_preprint":false},{"year":2010,"finding":"Raldh3 (ALDH1A3) overexpression reduces insulin secretion from β-cells (MIN6) and increases glucagon secretion from α-cells (αTC1 clone 9); knockdown of Raldh3 decreases glucagon secretion; 13-cis retinoic acid (the product of Raldh3 catalysis of 13-cis retinal) reduces cell viability specifically in MIN6 and αTC1 cells.","method":"Overexpression, siRNA knockdown, insulin/glucagon secretion assays, 13-cis retinoic acid treatment, cell viability assays in multiple cell lines","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with direct secretion readouts; product (13-cis RA) mechanistically linked to cell viability; single lab","pmids":["20833146"],"is_preprint":false},{"year":2021,"finding":"Nuclear ALDH1A3 in pulmonary arterial smooth muscle cells (PASMC) converts acetaldehyde to acetate, producing acetyl-CoA that acetylates histone H3K27 at active enhancers; this enables KAT2B acetyltransferase-mediated chromatin modification at NFYA binding sites and NFY-mediated transcription of cell cycle and metabolic genes required for SMC proliferation and glycolysis. Mice with SMC-specific Aldh1a3 deletion did not develop hypoxia-induced pulmonary arterial muscularization or pulmonary hypertension.","method":"RNA sequencing, nuclear fractionation and localization, metabolic flux analysis (acetaldehyde→acetate→acetyl-CoA), H3K27 acetylation ChIP, KAT2B acetyltransferase assays, NFYA ChIP, SMC-specific Aldh1a3 knockout mouse (hypoxia model), siRNA knockdown","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1 / Strong — nuclear metabolic-epigenetic mechanism with enzymatic substrate identification, ChIP for histone modification, acetyltransferase assay, tissue-specific KO mouse with in vivo phenotype; multiple orthogonal methods in single rigorous study","pmids":["33764154"],"is_preprint":false},{"year":2021,"finding":"ALDH1A3 stabilizes PKM2 by reducing its ubiquitination, thereby promoting aerobic glycolysis (Warburg effect) in colorectal cancer cells; ALDH1A3 and PKM2 interact as identified by co-immunoprecipitation followed by mass spectrometry.","method":"Co-immunoprecipitation with mass spectrometry (PKM2 identification), ubiquitination assay (PKM2 stabilization), glycolysis assays, siRNA knockdown","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP/MS for interaction identification, ubiquitination assay for mechanism; single lab","pmids":["33419984"],"is_preprint":false},{"year":2021,"finding":"A selective, competitive inhibitor (MCI-INI-3) targeting the active site of human ALDH1A3 was developed using the crystal structure of ALDH1A3; mass spectrometry-based cellular thermal shift analysis confirmed ALDH1A3 as the primary cellular binding protein; MCI-INI-3 inhibits retinoic acid biosynthesis comparably to ALDH1A3 knockout.","method":"Crystal structure of human ALDH1A3, in silico modeling, in vitro competitive inhibition assay, mass spectrometry-based cellular thermal shift assay (CETSA), ALDH1A3 knockout comparison","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with active-site inhibitor design, in vitro competitive inhibition assay, cellular target engagement by CETSA, knockout comparison; multiple orthogonal methods","pmids":["34934174"],"is_preprint":false},{"year":2021,"finding":"ALDH1A3 is the key isoform responsible for ALDH activity in cardiac atrial appendage progenitor cells; ALDH1A3 knockdown (but not ALDH1A1, ALDH1A2, ALDH2, ALDH4A1, or ALDH8A1) decreases ALDH activity and cell proliferation, while ALDH1A3 overexpression increases proliferation in ALDHlo cells.","method":"siRNA knockdown of individual ALDH isoforms, Aldefluor activity assay, retroviral overexpression, cell proliferation assay","journal":"Frontiers in cardiovascular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific siRNA with gain- and loss-of-function; direct functional readout (ALDH activity, proliferation); single lab","pmids":["30087899"],"is_preprint":false},{"year":2023,"finding":"Genetic or pharmacological inhibition of ALDH1A3 in diabetic mice lowers glycemia and increases insulin secretion; lineage tracing shows that ALDH1A3-positive β-cells (dedifferentiated) can be reconverted to functional mature β-cells upon ALDH1A3 inhibition, and ALDH1A3 inhibition reactivates differentiation and regeneration pathways.","method":"Somatic ALDH1A3 ablation (genetic), lineage tracing, selective pharmacological ALDH1A3 inhibitor treatment, glycemia measurement, insulin secretion assay, gene expression profiling","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic ablation and pharmacological inhibition with defined in vivo metabolic phenotypes; lineage tracing; multiple orthogonal approaches in single study","pmids":["36732513"],"is_preprint":false},{"year":2024,"finding":"ALDH1A3 interacts with PKM2 and enhances PKM2 tetramerization, promoting lactate accumulation in glioblastoma stem cells; accumulated lactate leads to lactylation of XRCC1 at K247, which increases XRCC1 affinity for importin α, enabling nuclear transposition of XRCC1 and enhanced DNA repair, thereby conferring chemoradiotherapy resistance.","method":"Co-immunoprecipitation (ALDH1A3-PKM2 interaction), lactylated proteome scanning by mass spectrometry, XRCC1-importin α binding assay, nuclear fractionation, high-throughput small molecule screening (D34-919 disrupts ALDH1A3-PKM2 interaction), in vitro and in vivo treatment","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 1 / Strong — Co-IP for protein-protein interaction, MS-based proteome scan, site-specific lactylation (K247) identified, importin α binding assay, nuclear localization, in vivo validation; multiple orthogonal methods in single rigorous study","pmids":["39111285"],"is_preprint":false},{"year":2024,"finding":"ALDH1A3 forms an enzymatic partnership with ACSS2 (acetyl-CoA synthetase 2) in the nucleus of melanoma cells, coupling glucose metabolic flux with acetyl-histone H3 modification of neural crest lineage and glucose metabolism genes; acetaldehyde serves as a metabolite source for acetyl-histone H3 modification in an ALDH1A3-dependent manner.","method":"Nuclear fractionation, ChIP for acetyl-H3 marks, metabolic flux analysis, ALDH1A3 inhibition/genetic manipulation, zebrafish melanoma residual disease model, ALDH1 suicide inhibitor (nifuroxazide)","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — nuclear ALDH1A3-ACSS2 partnership established with ChIP, metabolic flux linking acetaldehyde to acetyl-H3, in vivo zebrafish model; multiple orthogonal methods","pmids":["38963759"],"is_preprint":false},{"year":2024,"finding":"ALDH1A3 regulates the balance between two distinct breast cancer stem cell populations (ALDH+ and CD24-CD44+) via retinoic acid signaling-mediated gene expression; while ALDH1A3 increases ALDH+ cells, it inversely suppresses CD24-CD44+ cells. ALDH1A3 also increases oxidative phosphorylation and decreases glycolysis and ROS.","method":"ALDH1A3 knockdown/overexpression, Aldefluor assay, flow cytometry (CD44/CD24), metabolic assays (OXPHOS, glycolysis, ROS), retinoic acid signaling pathway inhibition, 2-DG (glycolysis inhibitor) rescue, xenograft tumor models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with multiple metabolic and cellular readouts; retinoic acid signaling mechanistically linked; single lab","pmids":["39251846"],"is_preprint":false},{"year":2023,"finding":"ALDH1A3 promotes invasion and metastasis of triple-negative breast cancer by regulating the plasminogen activation pathway: ALDH1A3 increases levels and activity of tPA and uPA, leading to increased plasmin activity; this invasion is plasminogen-dependent, and the ALDH1A3 product all-trans-retinoic acid similarly increases tPA and plasmin activity.","method":"ALDH1A3 knockdown/overexpression, tPA/uPA activity assays, plasmin activity assay, plasminogen-dependent invasion assays, retinoic acid treatment, tPA knockdown in vivo (lymph node metastasis model)","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity assays (plasmin, tPA, uPA), RA product mechanistically linked, in vivo metastasis model; single lab with multiple orthogonal approaches","pmids":["37753740"],"is_preprint":false},{"year":2018,"finding":"ALDH1A3 knockdown in glioblastoma reduces tumor cell invasion in vitro; ALDH1A3 is associated with mesenchymal transformation and drives changes in extracellular matrix organization and cell adhesion gene expression.","method":"siRNA/shRNA knockdown, Transwell invasion assay, Aldefluor flow cytometry, transcriptome analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — loss-of-function with direct invasion assay readout; single lab, single method for invasion","pmids":["30538217"],"is_preprint":false},{"year":2020,"finding":"ALDH1A3 promotes pancreatic cancer metastasis via metabolic regulation: ALDH1A3 activates PI3K/AKT/mTOR signaling and downstream PPARγ, which increases HK2 (hexokinase 2) expression and enhances glycolysis; pharmacological inhibition of PPARγ in ALDH1A3-positive cells impairs glycolytic gene expression and PI3K/AKT/mTOR activity.","method":"ALDH1A3 shRNA knockdown, overexpression, RNA-seq, glycolysis assays (glucose uptake, lactate, ATP), PPARγ inhibitor treatment, in vitro metastasis assays, in vivo metastasis models","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq pathway identification, pharmacologic epistasis (PPARγ inhibitor rescue), metabolic assays; single lab","pmids":["32612951"],"is_preprint":false},{"year":2020,"finding":"ALDH1A3 depletion affects mTOR cell survival pathway gene expression, coinciding with decreased activating phosphorylation of S6 kinase, placing ALDH1A3 upstream of mTOR signaling in drug-tolerant gastric cancer persister cells.","method":"RNA interference, gene expression analysis, Western blot (S6 kinase phosphorylation), mTOR inhibitor (temsirolimus) treatment, single-cell analysis, xenograft tumor models","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (ALDH1A3 depletion → mTOR pathway), signaling pathway validation by Western blot, pharmacologic confirmation; single lab","pmids":["31960523"],"is_preprint":false},{"year":2017,"finding":"miR-187 directly targets ALDH1A3 in prostate cancer cells; re-introduction of miR-187 in PC-3 cells downregulates ALDH1A3 protein and mRNA levels, identified by 2D-DIGE proteomics and validated by Western blot and qRT-PCR.","method":"2D-DIGE proteomics, MALDI-TOF MS, LC-MS/MS, Western blot, qRT-PCR, miR-187 precursor transfection","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomic identification with direct Western blot validation; miRNA-target relationship established; single lab, multiple methods","pmids":["25969992"],"is_preprint":false},{"year":2018,"finding":"PPARγ directly binds to a PPARγ response element (binding site 2) in the ALDH1A3 promoter and suppresses ALDH1A3 mRNA and protein expression upon ligand activation; ALDH1A3 suppression by PPARγ leads to accumulation of 4-HNE (lipid peroxidation marker) in PPARγ-positive lung cancer cells.","method":"NUBIscan in silico binding site prediction, ChIP assay (PPARγ binding to ALDH1A3 promoter BS2), QPCR, Western blot, PPARγ activator (TZD) treatment, 4-HNE Western blot","journal":"Journal of receptor and signal transduction research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirmed direct PPARγ binding to ALDH1A3 promoter; functional consequence shown (4-HNE accumulation); single lab","pmids":["29873276"],"is_preprint":false},{"year":2024,"finding":"ALDH1A3 contributes to tumorigenesis in high-grade serous ovarian cancer by increasing acetyl-CoA production, which leads to H3K27 acetylation at the PITX1 promoter and transcriptional activation of PITX1; ALDH1A3 knockdown reduces H3K27ac levels and PITX1 expression. ALDH1A3 expression is transcriptionally activated by HIF-1α.","method":"RNA-seq, siRNA knockdown, dual-luciferase reporter assay (HIF-1α→ALDH1A3 promoter), ChIP assay (H3K27ac at PITX1 promoter), exogenous acetate treatment (NaOAc), HDAC inhibitor (Pracinostat), HIF-1α inhibitor (KC7F2)","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for H3K27ac at PITX1 promoter, acetate rescue experiment, HIF-1α reporter assay; single lab with multiple orthogonal methods","pmids":["38211842"],"is_preprint":false},{"year":2023,"finding":"ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network; ALDH1A3 affects acetylation of histone H3, mediating AP-1 activity (particularly FOS family members) and activating MAPK and TNF signaling; RUNX2 knockdown disrupted MAPK signaling and reduced tumor growth.","method":"Chromatin profiling (H3 acetylation), functional interaction studies (FAM3C, MCC, PMEPA1, IRS2), RUNX2 knockdown, MAPK pathway analysis, xenograft tumor models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chromatin profiling linking ALDH1A3 to histone acetylation and AP-1 activity; RUNX2 epistasis; single lab","pmids":["40781158"],"is_preprint":false},{"year":2023,"finding":"ALDH1A3 knockdown in prostate cancer promotes cellular senescence-like phenotype while reducing SASP pro-inflammatory factor secretion via inhibition of the cGAS-STING pathway.","method":"ALDH1A3 siRNA knockdown, senescence assays, SASP factor measurement, cGAS-STING pathway analysis, radiotherapy in vitro model","journal":"Cancers","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pathway placement by knockdown with limited mechanistic validation of cGAS-STING link","pmids":["40227735"],"is_preprint":false},{"year":2016,"finding":"Compound heterozygous mutations in ALDH1A3 (c.287G>A and c.709G>A) cause anophthalmia; in vitro expression analysis showed that mutated alleles are associated with decreased protein production and impaired tetrameric protein formation.","method":"Exome sequencing, Sanger sequencing, in vitro expression analysis, native protein gel/tetrameric protein formation assay","journal":"Genetics and molecular biology","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — in vitro protein expression and tetramer formation assay; establishes protein quaternary structure requirement; single study","pmids":["28590501"],"is_preprint":false},{"year":2021,"finding":"ALDH1A3 and ALDH1A1 paralogues are both pivotal for myogenic differentiation of skeletal muscle satellite cells (C2C12 myoblasts): CRISPR/Cas9 single-paralogue knockout impairs differentiation, and retinoic acid (RA) analogue TTNPB restores differentiation in knockout cells. ALDH1-paralogue knockout also impairs autophagic flux (p62 formation and LC3B-I to LC3B-II conversion).","method":"CRISPR/Cas9 knockout, recombinant ALDH1A3 re-expression rescue, RA analogue (TTNPB) treatment, RA receptor antagonist (AGN 193109) treatment, autophagy flux assays (p62, LC3B Western blot)","journal":"Cell and tissue research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with genetic rescue by re-expression, RA pathway epistasis, autophagy flux assay; single lab with multiple orthogonal methods","pmids":["37904003"],"is_preprint":false}],"current_model":"ALDH1A3 is a retinaldehyde dehydrogenase (NAD+-dependent) that oxidizes retinaldehyde to retinoic acid, and in the nucleus also converts acetaldehyde to acetate, generating acetyl-CoA that drives H3K27 acetylation at enhancers/promoters to epigenetically regulate cell cycle, metabolic, and lineage genes; it stabilizes PKM2 through direct protein interaction to promote glycolysis and lactate-mediated XRCC1 lactylation; it is post-translationally regulated by USP9X-mediated deubiquitination (stabilizing it) and by autophagy/p62-mediated degradation; transcriptionally it is controlled by FOXD1, CEBPβ (via STAT3-NFkB-DDIT3 axis), HIF-1α, androgen receptor, and CHD7; upstream RNA-level regulation occurs via Sam68-mediated prevention of intronic polyadenylation; the enzyme is critical for retinoic acid-dependent developmental patterning of the eye, inner ear, forebrain, and olfactory system, and its loss-of-function causes human autosomal recessive anophthalmia/microphthalmia."},"narrative":{"mechanistic_narrative":"ALDH1A3 is an NAD+-dependent retinaldehyde dehydrogenase that oxidizes retinaldehyde to retinoic acid and, through this activity, drives retinoic acid-dependent developmental patterning of the eye, inner ear, and ventral forebrain [PMID:11025231, PMID:11044606, PMID:17207476]. It is expressed selectively in ventral retina, otic vesicle, and olfactory pit during embryogenesis, where its retinoic acid output is required for ventral forebrain RA signaling and dopamine receptor D2 expression [PMID:11025231, PMID:11044606, PMID:17207476]. Loss-of-function mutations in ALDH1A3 cause human autosomal recessive anophthalmia/microphthalmia, with pathogenic alleles acting predominantly through reduced protein accumulation and impaired tetramer formation rather than loss of intrinsic catalysis [PMID:23312594, PMID:23591992, PMID:23646827, PMID:23881059, PMID:28590501]; the developmental requirement is conserved, as aldh1a3 knockdown reduces eye size in zebrafish [PMID:23591992]. Beyond its developmental role, ALDH1A3 is the dominant ALDH isoform underlying ALDH activity in breast cancer, glioma, and cardiac progenitor stem-cell populations and sustains their self-renewal and tumorigenicity [PMID:21280157, PMID:30087899]. A nuclear, non-canonical function couples metabolism to chromatin: nuclear ALDH1A3 oxidizes acetaldehyde to acetate, generating acetyl-CoA — in partnership with the acetyl-CoA synthetase ACSS2 — that fuels H3K27/histone H3 acetylation at enhancers and promoters of cell-cycle, metabolic, and lineage genes, a mechanism required for smooth muscle proliferation in pulmonary hypertension, melanoma neural-crest gene programs, and ovarian and pancreatic cancer transcriptional networks [PMID:33764154, PMID:38963759, PMID:38211842, PMID:40781158]. ALDH1A3 also acts independently of catalysis through direct protein interactions, binding and stabilizing PKM2 to promote aerobic glycolysis and, via enhanced PKM2 tetramerization and lactate production, driving lactylation-dependent nuclear import of XRCC1 and DNA-repair-mediated therapy resistance [PMID:33419984, PMID:39111285]. Its abundance is set post-translationally by USP9X-mediated deubiquitination that stabilizes the protein and by p62/autophagy-mediated degradation [PMID:30958800, PMID:29306018], transcriptionally by FOXD1, CEBPβ (downstream of a STAT3-NFκB-DDIT3 axis), HIF-1α, PPARγ, the androgen receptor, and the chromatin remodeler CHD7 [PMID:27569208, PMID:25868979, PMID:38211842, PMID:29873276, PMID:17526768, PMID:29467333], and at the RNA level by Sam68-dependent suppression of intronic polyadenylation that permits full-length transcript expression [PMID:27845622]. A crystal structure of human ALDH1A3 has enabled active-site-directed competitive inhibitors that phenocopy genetic loss [PMID:34934174].","teleology":[{"year":1994,"claim":"Establishing ALDH1A3 as a discrete aldehyde dehydrogenase isozyme with defined gene structure and tissue distribution provided the molecular foundation for all subsequent functional study.","evidence":"cDNA cloning, Northern blot, and FISH chromosomal mapping","pmids":["7698756"],"confidence":"High","gaps":["Did not define the physiological substrate or enzymatic specificity","No developmental or disease role assigned"]},{"year":2000,"claim":"Identifying retinaldehyde as the substrate and retinoic acid as the product, with spatially restricted embryonic expression, defined ALDH1A3 as a region-specific generator of the morphogen retinoic acid.","evidence":"cDNA cloning, in vitro enzymatic activity assay, in situ hybridization in mouse and chick embryos, Pax6 mutant analysis","pmids":["11025231","11044606"],"confidence":"High","gaps":["Did not establish in vivo developmental requirement","Upstream regulators beyond Pax6 unresolved"]},{"year":2006,"claim":"Loss-of-function genetics demonstrated that ALDH1A3-derived retinoic acid is required for ventral forebrain patterning, moving the gene from a marker to a causal developmental signal.","evidence":"Raldh2/Raldh3 single and double null mouse epistasis with RA reporter and in situ readouts","pmids":["17207476"],"confidence":"High","gaps":["Downstream transcriptional targets of RA in forebrain not fully mapped"]},{"year":2013,"claim":"Human genetics and zebrafish modeling established ALDH1A3 as a cause of autosomal recessive anophthalmia/microphthalmia, linking enzyme deficiency to congenital eye malformation.","evidence":"Homozygosity mapping, exome sequencing, mutant protein expression assays, in vitro enzymatic assay, zebrafish morpholino knockdown","pmids":["23312594","23591992","23646827","23881059"],"confidence":"High","gaps":["Not all mutations impair catalysis (p.Val71Met retained activity), implicating stability/folding","Exact developmental window of pathogenesis unresolved"]},{"year":2016,"claim":"Native gel analysis of mutant alleles showed that pathogenic mutations impair tetrameric assembly and protein production, clarifying that protein stability, not always catalysis, underlies disease.","evidence":"In vitro expression and tetramer formation assays of mutant alleles","pmids":["28590501"],"confidence":"Medium","gaps":["Quaternary structure requirement not tested in vivo","Folding chaperone or degradation pathway for unstable mutants not identified"]},{"year":2011,"claim":"Isoform-specific knockdown revealed ALDH1A3 as the principal contributor to the ALDH activity that marks cancer stem cells, recasting the enzyme as a stem-cell functional determinant.","evidence":"Genome microarray, shRNA knockdown, Aldefluor assay across breast cancer cell lines and patient CSCs","pmids":["21280157"],"confidence":"High","gaps":["Mechanism linking ALDH activity to stemness not defined at this stage"]},{"year":2016,"claim":"Multiple regulatory inputs were mapped — transcriptional control by FOXD1 and a STAT3-NFκB-DDIT3-CEBPβ axis, and RNA-level control by Sam68-dependent suppression of intronic polyadenylation — explaining how ALDH1A3 levels are tuned in stem and cancer cells.","evidence":"shRNA/RNAi, promoter and luciferase reporter assays, ChIP, co-IP, Khdrbs1 knockout mouse with pre-mRNA 3'-processing assays","pmids":["27569208","25868979","27845622"],"confidence":"High","gaps":["Combinatorial integration of these regulators in a given tissue unresolved","Sam68-ALDH1A3 axis tested mainly in neural progenitors"]},{"year":2018,"claim":"Post-translational control was established through p62/autophagy-mediated degradation and CHD7-mediated transcriptional repression, expanding the regulatory layers governing ALDH1A3 abundance.","evidence":"Co-IP (ALDH1A3-p62), mRNA-vs-protein comparison, autophagy modulation; CHD7 chromatin binding and Chd7/Aldh1a3 double-mutant mouse rescue","pmids":["29306018","29467333"],"confidence":"High","gaps":["E3 ligase upstream of autophagic turnover not identified","Direct vs indirect CHD7 repression mechanism only partly resolved"]},{"year":2019,"claim":"USP9X was identified as a deubiquitinase that stabilizes ALDH1A3, establishing the ubiquitin-proteasome counterbalance to its degradation and a node sustaining glioblastoma stem-cell self-renewal.","evidence":"Reciprocal co-IP, depolyubiquitylation assays, USP9X depletion with ALDH1A3 rescue, orthotopic xenografts, USP9X inhibitor","pmids":["30958800"],"confidence":"High","gaps":["The opposing E3 ubiquitin ligase remains unidentified","Whether USP9X regulation is tissue-restricted unknown"]},{"year":2021,"claim":"The discovery that nuclear ALDH1A3 converts acetaldehyde to acetate to generate acetyl-CoA for histone H3K27 acetylation revealed a moonlighting metabolic-epigenetic function distinct from retinoic acid signaling.","evidence":"Nuclear fractionation, metabolic flux analysis, H3K27ac and NFYA ChIP, KAT2B acetyltransferase assay, SMC-specific Aldh1a3 knockout mouse in hypoxia","pmids":["33764154"],"confidence":"High","gaps":["Determinants of nuclear vs cytoplasmic ALDH1A3 partitioning not defined","Generality across cell types established only later"]},{"year":2021,"claim":"Structure-guided inhibitor development produced a selective active-site competitive inhibitor that phenocopies ALDH1A3 knockout, providing a chemical tool and validating the active site as a target.","evidence":"Human ALDH1A3 crystal structure, in silico modeling, competitive inhibition assay, CETSA target engagement, knockout comparison","pmids":["34934174"],"confidence":"High","gaps":["Inhibitor does not address non-catalytic protein-interaction functions"]},{"year":2021,"claim":"Identification of a direct ALDH1A3-PKM2 interaction that stabilizes PKM2 and promotes aerobic glycolysis revealed a non-enzymatic, scaffolding role in tumor metabolism.","evidence":"Co-IP/mass spectrometry, PKM2 ubiquitination assay, glycolysis assays, siRNA knockdown in colorectal cancer cells","pmids":["33419984"],"confidence":"Medium","gaps":["Interaction interface and whether catalysis is required not defined","Single cancer context"]},{"year":2024,"claim":"Mechanistic dissection extended the nuclear acetyl-CoA/ACSS2 axis to melanoma lineage and ovarian/pancreatic cancer transcriptional networks, and connected the PKM2 interaction to lactate-driven XRCC1 lactylation and DNA-repair-mediated therapy resistance.","evidence":"Nuclear fractionation, ChIP for acetyl-H3/H3K27ac, metabolic flux, lactylated-proteome MS, XRCC1-importinα binding, zebrafish melanoma model, small-molecule disruptors","pmids":["38963759","39111285","38211842","40781158"],"confidence":"High","gaps":["Quantitative contribution of nuclear vs cytosolic acetyl-CoA pools unresolved","How a single enzyme coordinates metabolic and chromatin functions in vivo not fully resolved"]},{"year":2023,"claim":"ALDH1A3 was implicated in beta-cell dedifferentiation, with inhibition reconverting dedifferentiated beta-cells to functional mature cells, revealing a role in cellular identity beyond cancer and development.","evidence":"Genetic ablation, lineage tracing, selective pharmacological inhibition, glycemia and insulin secretion assays in diabetic mice","pmids":["36732513"],"confidence":"High","gaps":["Whether the metabolic-epigenetic or RA function drives dedifferentiation not separated","Mechanism of reversal incompletely defined"]},{"year":null,"claim":"How ALDH1A3's three modes — retinoic acid synthesis, nuclear acetyl-CoA generation for histone acetylation, and catalysis-independent protein stabilization of PKM2 — are partitioned and coordinated within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No determinant identified that controls nuclear vs cytoplasmic localization","Relative weighting of enzymatic vs scaffolding functions across tissues unknown","No integrated structure-function model linking tetramerization, catalysis, and protein interactions"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,2,4,19,21,25]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[19,25]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[20,24]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[19,24,25]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,3,6,7,13]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[19,20,24,25,29]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[19,25,33,34]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[6,36]}],"complexes":[],"partners":["PKM2","USP9X","SQSTM1","ACSS2","KHDRBS1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P47895","full_name":"Retinaldehyde dehydrogenase 3","aliases":["Aldehyde dehydrogenase 6","Aldehyde dehydrogenase family 1 member A3","ALDH1A3"],"length_aa":512,"mass_kda":56.1,"function":"Catalyzes the NAD-dependent oxidation of aldehyde substrates, such as all-trans-retinal and all-trans-13,14-dihydroretinal, to their corresponding carboxylic acids, all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively (By similarity) (PubMed:27759097). High specificity for all-trans-retinal as substrate, can also accept acetaldehyde as substrate in vitro but with lower affinity (PubMed:27759097). Required for the biosynthesis of normal levels of retinoate in the embryonic ocular and nasal regions; a critical lipid in the embryonic development of the eye and the nasal region (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P47895/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ALDH1A3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ALDH1A3","total_profiled":1310},"omim":[{"mim_id":"615113","title":"MICROPHTHALMIA, ISOLATED 8; MCOP8","url":"https://www.omim.org/entry/615113"},{"mim_id":"600463","title":"ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER A3; ALDH1A3","url":"https://www.omim.org/entry/600463"},{"mim_id":"251600","title":"MICROPHTHALMIA, ISOLATED 1; MCOP1","url":"https://www.omim.org/entry/251600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"prostate","ntpm":126.3},{"tissue":"urinary bladder","ntpm":116.7}],"url":"https://www.proteinatlas.org/search/ALDH1A3"},"hgnc":{"alias_symbol":["RALDH3"],"prev_symbol":["ALDH6"]},"alphafold":{"accession":"P47895","domains":[{"cath_id":"3.40.605.10","chopping":"33-281","consensus_level":"high","plddt":98.2267,"start":33,"end":281},{"cath_id":"3.40.309.10","chopping":"285-473","consensus_level":"high","plddt":97.7951,"start":285,"end":473}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P47895","model_url":"https://alphafold.ebi.ac.uk/files/AF-P47895-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P47895-F1-predicted_aligned_error_v6.png","plddt_mean":95.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ALDH1A3","jax_strain_url":"https://www.jax.org/strain/search?query=ALDH1A3"},"sequence":{"accession":"P47895","fasta_url":"https://rest.uniprot.org/uniprotkb/P47895.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P47895/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P47895"}},"corpus_meta":[{"pmid":"21280157","id":"PMC_21280157","title":"Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.","date":"2011","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/21280157","citation_count":380,"is_preprint":false},{"pmid":"39111285","id":"PMC_39111285","title":"Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma.","date":"2024","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39111285","citation_count":166,"is_preprint":false},{"pmid":"11025231","id":"PMC_11025231","title":"RALDH3, a retinaldehyde dehydrogenase that generates retinoic acid, is expressed in the ventral retina, otic vesicle and olfactory pit during mouse development.","date":"2000","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11025231","citation_count":135,"is_preprint":false},{"pmid":"27569208","id":"PMC_27569208","title":"FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27569208","citation_count":128,"is_preprint":false},{"pmid":"26991532","id":"PMC_26991532","title":"ALDH1A3, a metabolic target for cancer diagnosis and therapy.","date":"2016","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26991532","citation_count":109,"is_preprint":false},{"pmid":"31197235","id":"PMC_31197235","title":"ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31197235","citation_count":95,"is_preprint":false},{"pmid":"11044606","id":"PMC_11044606","title":"Identification of RALDH-3, a novel retinaldehyde dehydrogenase, expressed in the ventral region of the retina.","date":"2000","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11044606","citation_count":95,"is_preprint":false},{"pmid":"33764154","id":"PMC_33764154","title":"ALDH1A3 Coordinates Metabolism With Gene Regulation in Pulmonary Arterial Hypertension.","date":"2021","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/33764154","citation_count":90,"is_preprint":false},{"pmid":"17207476","id":"PMC_17207476","title":"Role of retinoic acid during forebrain development begins late when Raldh3 generates retinoic acid in the ventral subventricular zone.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17207476","citation_count":85,"is_preprint":false},{"pmid":"23312594","id":"PMC_23312594","title":"ALDH1A3 mutations cause recessive anophthalmia and microphthalmia.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23312594","citation_count":83,"is_preprint":false},{"pmid":"30958800","id":"PMC_30958800","title":"USP9X deubiquitinates ALDH1A3 and maintains mesenchymal identity in glioblastoma stem cells.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30958800","citation_count":81,"is_preprint":false},{"pmid":"28937653","id":"PMC_28937653","title":"Differential Functional Roles of ALDH1A1 and ALDH1A3 in Mediating Metastatic Behavior and Therapy Resistance of Human Breast Cancer Cells.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28937653","citation_count":79,"is_preprint":false},{"pmid":"27592281","id":"PMC_27592281","title":"Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3.","date":"2016","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27592281","citation_count":72,"is_preprint":false},{"pmid":"25868979","id":"PMC_25868979","title":"A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25868979","citation_count":69,"is_preprint":false},{"pmid":"23591992","id":"PMC_23591992","title":"ALDH1A3 loss of function causes bilateral anophthalmia/microphthalmia and hypoplasia of the optic nerve and optic chiasm.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23591992","citation_count":63,"is_preprint":false},{"pmid":"33419984","id":"PMC_33419984","title":"Diethyldithiocarbamate-copper complex (CuET) inhibits colorectal cancer progression via miR-16-5p and 15b-5p/ALDH1A3/PKM2 axis-mediated aerobic glycolysis pathway.","date":"2021","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33419984","citation_count":58,"is_preprint":false},{"pmid":"25969992","id":"PMC_25969992","title":"MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25969992","citation_count":56,"is_preprint":false},{"pmid":"27845622","id":"PMC_27845622","title":"Sam68 promotes self-renewal and glycolytic metabolism in mouse neural progenitor cells by modulating Aldh1a3 pre-mRNA 3'-end processing.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27845622","citation_count":55,"is_preprint":false},{"pmid":"18178530","id":"PMC_18178530","title":"Expression of zebrafish aldh1a3 (raldh3) and absence of aldh1a1 in teleosts.","date":"2007","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/18178530","citation_count":52,"is_preprint":false},{"pmid":"28581514","id":"PMC_28581514","title":"ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28581514","citation_count":52,"is_preprint":false},{"pmid":"36732513","id":"PMC_36732513","title":"Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36732513","citation_count":51,"is_preprint":false},{"pmid":"7698756","id":"PMC_7698756","title":"Molecular cloning, genomic organization, and chromosomal localization of an additional human aldehyde dehydrogenase gene, ALDH6.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7698756","citation_count":51,"is_preprint":false},{"pmid":"29235568","id":"PMC_29235568","title":"ALDH1A3 affects colon cancer in vitro proliferation and invasion depending on CXCR4 status.","date":"2017","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29235568","citation_count":50,"is_preprint":false},{"pmid":"30143021","id":"PMC_30143021","title":"ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30143021","citation_count":49,"is_preprint":false},{"pmid":"30538217","id":"PMC_30538217","title":"ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30538217","citation_count":48,"is_preprint":false},{"pmid":"28423611","id":"PMC_28423611","title":"The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28423611","citation_count":45,"is_preprint":false},{"pmid":"32612951","id":"PMC_32612951","title":"ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32612951","citation_count":41,"is_preprint":false},{"pmid":"17526768","id":"PMC_17526768","title":"Androgen regulation of aldehyde dehydrogenase 1A3 (ALDH1A3) in the androgen-responsive human prostate cancer cell line LNCaP.","date":"2007","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/17526768","citation_count":41,"is_preprint":false},{"pmid":"29306018","id":"PMC_29306018","title":"Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29306018","citation_count":38,"is_preprint":false},{"pmid":"31960523","id":"PMC_31960523","title":"ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer.","date":"2020","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/31960523","citation_count":38,"is_preprint":false},{"pmid":"17180597","id":"PMC_17180597","title":"Expression of retinaldehyde dehydrogenase (RALDH)2 and RALDH3 but not RALDH1 in the developing anterior pituitary glands of rats.","date":"2006","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/17180597","citation_count":36,"is_preprint":false},{"pmid":"26575197","id":"PMC_26575197","title":"ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26575197","citation_count":33,"is_preprint":false},{"pmid":"36672441","id":"PMC_36672441","title":"The Expanding Role of Cancer Stem Cell Marker ALDH1A3 in Cancer and Beyond.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36672441","citation_count":32,"is_preprint":false},{"pmid":"34934174","id":"PMC_34934174","title":"A specific inhibitor of ALDH1A3 regulates retinoic acid biosynthesis in glioma stem cells.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34934174","citation_count":32,"is_preprint":false},{"pmid":"29720480","id":"PMC_29720480","title":"Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/29720480","citation_count":32,"is_preprint":false},{"pmid":"18262854","id":"PMC_18262854","title":"Expressions of Raldh3 and Raldh4 during zebrafish early development.","date":"2008","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/18262854","citation_count":31,"is_preprint":false},{"pmid":"32127468","id":"PMC_32127468","title":"Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32127468","citation_count":29,"is_preprint":false},{"pmid":"31347176","id":"PMC_31347176","title":"Inhibition of breast cancer growth via miR-7 suppressing ALDH1A3 activity concomitant with decreasing breast cancer stem cell subpopulation.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31347176","citation_count":29,"is_preprint":false},{"pmid":"24024553","id":"PMC_24024553","title":"A homozygous mutation in a consanguineous family consolidates the role of ALDH1A3 in autosomal recessive microphthalmia.","date":"2013","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24024553","citation_count":29,"is_preprint":false},{"pmid":"27286452","id":"PMC_27286452","title":"Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27286452","citation_count":27,"is_preprint":false},{"pmid":"29467333","id":"PMC_29467333","title":"CHD7 represses the retinoic acid synthesis enzyme ALDH1A3 during inner ear development.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29467333","citation_count":27,"is_preprint":false},{"pmid":"15245423","id":"PMC_15245423","title":"Hair cycle-specific immunolocalization of retinoic acid synthesizing enzymes Aldh1a2 and Aldh1a3 indicate complex regulation.","date":"2004","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15245423","citation_count":27,"is_preprint":false},{"pmid":"31513972","id":"PMC_31513972","title":"ALDH1A3 Regulations of Matricellular Proteins Promote Vascular Smooth Muscle Cell Proliferation.","date":"2019","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/31513972","citation_count":26,"is_preprint":false},{"pmid":"26352270","id":"PMC_26352270","title":"Whole-Exome Sequencing in a South American Cohort Links ALDH1A3, FOXN1 and Retinoic Acid Regulation Pathways to Autism Spectrum Disorders.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26352270","citation_count":26,"is_preprint":false},{"pmid":"23646827","id":"PMC_23646827","title":"Mutations in ALDH1A3 cause microphthalmia.","date":"2013","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23646827","citation_count":26,"is_preprint":false},{"pmid":"23881059","id":"PMC_23881059","title":"A missense mutation in ALDH1A3 causes isolated microphthalmia/anophthalmia in nine individuals from an inbred Muslim kindred.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/23881059","citation_count":25,"is_preprint":false},{"pmid":"32270866","id":"PMC_32270866","title":"MIR600HG suppresses metastasis and enhances oxaliplatin chemosensitivity by targeting ALDH1A3 in colorectal cancer.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32270866","citation_count":24,"is_preprint":false},{"pmid":"31580832","id":"PMC_31580832","title":"Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes.","date":"2019","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/31580832","citation_count":21,"is_preprint":false},{"pmid":"18647663","id":"PMC_18647663","title":"Expression patterns of Shh, Ptc2, Raldh3, Pitx2, Isl1, Lim3 and Pax6 in the developing chick hypophyseal placode and Rathke's pouch.","date":"2008","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/18647663","citation_count":21,"is_preprint":false},{"pmid":"25656374","id":"PMC_25656374","title":"Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.","date":"2015","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25656374","citation_count":21,"is_preprint":false},{"pmid":"27706811","id":"PMC_27706811","title":"Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam.","date":"2016","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27706811","citation_count":21,"is_preprint":false},{"pmid":"24777706","id":"PMC_24777706","title":"Mutations in ALDH1A3 represent a frequent cause of microphthalmia/anophthalmia in consanguineous families.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24777706","citation_count":21,"is_preprint":false},{"pmid":"30087899","id":"PMC_30087899","title":"ALDH1A3 Is the Key Isoform That Contributes to Aldehyde Dehydrogenase Activity and Affects in Vitro Proliferation in Cardiac Atrial Appendage Progenitor Cells.","date":"2018","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30087899","citation_count":21,"is_preprint":false},{"pmid":"35831872","id":"PMC_35831872","title":"circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3.","date":"2022","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/35831872","citation_count":20,"is_preprint":false},{"pmid":"33564883","id":"PMC_33564883","title":"microRNA-483 Protects Pancreatic β-Cells by Targeting ALDH1A3.","date":"2021","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33564883","citation_count":19,"is_preprint":false},{"pmid":"24568872","id":"PMC_24568872","title":"Novel splice-site and missense mutations in the ALDH1A3 gene underlying autosomal recessive anophthalmia/microphthalmia.","date":"2014","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/24568872","citation_count":19,"is_preprint":false},{"pmid":"27569851","id":"PMC_27569851","title":"Expression of retinoic acid-metabolizing enzymes, ALDH1A1, ALDH1A2, ALDH1A3, CYP26A1, CYP26B1 and CYP26C1 in canine testis during post-natal development.","date":"2016","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/27569851","citation_count":18,"is_preprint":false},{"pmid":"33125503","id":"PMC_33125503","title":"MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33125503","citation_count":17,"is_preprint":false},{"pmid":"37947601","id":"PMC_37947601","title":"Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37947601","citation_count":17,"is_preprint":false},{"pmid":"26873617","id":"PMC_26873617","title":"Incomplete penetrance of biallelic ALDH1A3 mutations.","date":"2016","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26873617","citation_count":17,"is_preprint":false},{"pmid":"28443495","id":"PMC_28443495","title":"ALDH1A3 correlates with luminal phenotype in prostate cancer.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28443495","citation_count":15,"is_preprint":false},{"pmid":"32375698","id":"PMC_32375698","title":"ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients.","date":"2020","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32375698","citation_count":15,"is_preprint":false},{"pmid":"30200890","id":"PMC_30200890","title":"Novel mutations in ALDH1A3 associated with autosomal recessive anophthalmia/microphthalmia, and review of the literature.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30200890","citation_count":15,"is_preprint":false},{"pmid":"27917009","id":"PMC_27917009","title":"Induced Expression of Cancer Stem Cell Markers ALDH1A3 and Sox-2 in Hierarchical Reconstitution of Apoptosis-resistant Human Breast Cancer Cells.","date":"2016","source":"Acta histochemica et cytochemica","url":"https://pubmed.ncbi.nlm.nih.gov/27917009","citation_count":15,"is_preprint":false},{"pmid":"39251846","id":"PMC_39251846","title":"ALDH1A3 is the switch that determines the balance of ALDH+ and CD24-CD44+ cancer stem cells, EMT-MET, and glucose metabolism in breast cancer.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39251846","citation_count":14,"is_preprint":false},{"pmid":"20833146","id":"PMC_20833146","title":"Raldh3 expression in diabetic islets reciprocally regulates secretion of insulin and glucagon from pancreatic islets.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20833146","citation_count":13,"is_preprint":false},{"pmid":"29873276","id":"PMC_29873276","title":"PPARgamma-mediated ALDH1A3 suppression exerts anti-proliferative effects in lung cancer by inducing lipid peroxidation.","date":"2018","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/29873276","citation_count":13,"is_preprint":false},{"pmid":"38963759","id":"PMC_38963759","title":"ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38963759","citation_count":12,"is_preprint":false},{"pmid":"33403039","id":"PMC_33403039","title":"ADP-Ribosylation Factor Like GTPase 4C (ARL4C) augments stem-like traits of glioblastoma cells by upregulating ALDH1A3.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33403039","citation_count":12,"is_preprint":false},{"pmid":"35052687","id":"PMC_35052687","title":"ALDH1A3 Segregated Expression and Nucleus-Associated Proteasomal Degradation Are Common Traits of Glioblastoma Stem Cells.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35052687","citation_count":11,"is_preprint":false},{"pmid":"35598658","id":"PMC_35598658","title":"Lactic acidosis promotes aggressive features of cholangiocarcinoma cells via upregulating ALDH1A3 expression through EGFR axis.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35598658","citation_count":11,"is_preprint":false},{"pmid":"34641313","id":"PMC_34641313","title":"Design, Synthesis, Biological Evaluation and In Silico Study of Benzyloxybenzaldehyde Derivatives as Selective ALDH1A3 Inhibitors.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34641313","citation_count":11,"is_preprint":false},{"pmid":"36980923","id":"PMC_36980923","title":"EGFRvIII Promotes the Proneural-Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-κB/ALDH1A3 Axis.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36980923","citation_count":11,"is_preprint":false},{"pmid":"37551838","id":"PMC_37551838","title":"MiR-4524b-5p-targeting ALDH1A3 attenuates the proliferation and radioresistance of glioblastoma via PI3K/AKT/mTOR signaling.","date":"2023","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37551838","citation_count":10,"is_preprint":false},{"pmid":"36975509","id":"PMC_36975509","title":"In Vitro Evaluation of ALDH1A3-Affinic Compounds on Breast and Prostate Cancer Cell Lines as Single Treatments and in Combination with Doxorubicin.","date":"2023","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/36975509","citation_count":9,"is_preprint":false},{"pmid":"28590501","id":"PMC_28590501","title":"Novel compound heterozygous mutations of ALDH1A3 contribute to anophthalmia in a non-consanguineous Chinese family.","date":"2017","source":"Genetics and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28590501","citation_count":9,"is_preprint":false},{"pmid":"37047661","id":"PMC_37047661","title":"A Selective ALDH1A3 Inhibitor Impairs Mesothelioma 3-D Multicellular Spheroid Growth and Neutrophil Recruitment.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37047661","citation_count":8,"is_preprint":false},{"pmid":"38160009","id":"PMC_38160009","title":"Luminal B Breast Cancer Coexpressing p62 and ALDH1A3 Is Less Susceptible to Radiotherapy.","date":"2024","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38160009","citation_count":8,"is_preprint":false},{"pmid":"37753740","id":"PMC_37753740","title":"ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway.","date":"2023","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37753740","citation_count":7,"is_preprint":false},{"pmid":"38669046","id":"PMC_38669046","title":"Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.","date":"2024","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38669046","citation_count":7,"is_preprint":false},{"pmid":"40198404","id":"PMC_40198404","title":"PPAR γ changing ALDH1A3 content to regulate lipid metabolism and inhibit lung cancer cell growth.","date":"2025","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/40198404","citation_count":6,"is_preprint":false},{"pmid":"37904003","id":"PMC_37904003","title":"ALDH1A1 and ALDH1A3 paralogues of aldehyde dehydrogenase 1 control myogenic differentiation of skeletal muscle satellite cells by retinoic acid-dependent and -independent mechanisms.","date":"2023","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/37904003","citation_count":6,"is_preprint":false},{"pmid":"36275636","id":"PMC_36275636","title":"ALDH1A3-Linc00284 Axis Mediates the Invasion of Colorectal Cancer by Targeting TGFβ Signaling via Sponging miR-361-5p.","date":"2022","source":"International journal of genomics","url":"https://pubmed.ncbi.nlm.nih.gov/36275636","citation_count":6,"is_preprint":false},{"pmid":"36050388","id":"PMC_36050388","title":"Curcumin-based-fluorescent probes targeting ALDH1A3 as a promising tool for glioblastoma precision surgery and early diagnosis.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36050388","citation_count":6,"is_preprint":false},{"pmid":"40480147","id":"PMC_40480147","title":"tsRNA-08614 inhibits glycolysis and histone lactylation by ALDH1A3 to confer oxaliplatin sensitivity in colorectal cancer.","date":"2025","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40480147","citation_count":5,"is_preprint":false},{"pmid":"36996494","id":"PMC_36996494","title":"MiR-320b aberrant expression enhances the radioresistance of human glioma via upregulated expression of ALDH1A3.","date":"2023","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/36996494","citation_count":5,"is_preprint":false},{"pmid":"40365730","id":"PMC_40365730","title":"Oral 7,8-Dihydroxyflavone Protects Retinal Ganglion Cells by Modulating the Gut-Retina Axis and Inhibiting Ferroptosis via the Indoleacrylic Acid-AhR-ALDH1A3-FSP1 Pathway.","date":"2025","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/40365730","citation_count":5,"is_preprint":false},{"pmid":"37686698","id":"PMC_37686698","title":"Novel Function of Cancer Stem Cell Marker ALDH1A3 in Glioblastoma: Pro-Angiogenesis through Paracrine PAI-1 and IL-8.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37686698","citation_count":5,"is_preprint":false},{"pmid":"34504547","id":"PMC_34504547","title":"Knockdown of ALDH1A3 reduces breast cancer stem cell marker CD44 via the miR-7-TGFBR2-Smad3-CD44 regulatory axis.","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34504547","citation_count":5,"is_preprint":false},{"pmid":"36334047","id":"PMC_36334047","title":"Identification of a novel ALDH1A3-selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinity-based drug target discovery.","date":"2022","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/36334047","citation_count":5,"is_preprint":false},{"pmid":"38211842","id":"PMC_38211842","title":"ALDH1A3 contributes to tumorigenesis in high-grade serous ovarian cancer by epigenetic modification.","date":"2024","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/38211842","citation_count":4,"is_preprint":false},{"pmid":"34440089","id":"PMC_34440089","title":"Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/34440089","citation_count":4,"is_preprint":false},{"pmid":"30958802","id":"PMC_30958802","title":"Deubiquitinating ALDH1A3 key to maintaining the culprit of aggressive brain cancer.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30958802","citation_count":4,"is_preprint":false},{"pmid":"40227735","id":"PMC_40227735","title":"ALDH1A3 Regulates Cellular Senescence and Senescence-Associated Secretome in Prostate Cancer.","date":"2025","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/40227735","citation_count":3,"is_preprint":false},{"pmid":"37339696","id":"PMC_37339696","title":"ALDH1A3-related congenital microphthalmia-8 due to a novel frameshift variant.","date":"2023","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37339696","citation_count":3,"is_preprint":false},{"pmid":"19455414","id":"PMC_19455414","title":"Opossum aldehyde dehydrogenases: evidence for four ALDH1A1-like genes on chromosome 6 and ALDH1A2 and ALDH1A3 genes on chromosome 1.","date":"2009","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19455414","citation_count":3,"is_preprint":false},{"pmid":"18406560","id":"PMC_18406560","title":"Regulation of RALDH-1, RALDH-3 and CYP26A1 by transcription factors cVax/Vax2 and Tbx5 in the embryonic chick retina.","date":"2008","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18406560","citation_count":3,"is_preprint":false},{"pmid":"40781158","id":"PMC_40781158","title":"ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network.","date":"2025","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/40781158","citation_count":2,"is_preprint":false},{"pmid":"39555365","id":"PMC_39555365","title":"Expression of cancer stem cell markers (CD24, CD44 & ALDH1A3 isoform) in Breast Cancer in Indian population considering clinicopathological characteristics and response to neoadjuvant chemotherapy - a prospective analysis from a university hospital.","date":"2024","source":"Indian journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39555365","citation_count":2,"is_preprint":false},{"pmid":"41179310","id":"PMC_41179310","title":"High p62 and ALDH1A3 Reduce the Effectiveness of Endocrine Therapy in Luminal B Breast Cancer.","date":"2025","source":"Cancer diagnosis & prognosis","url":"https://pubmed.ncbi.nlm.nih.gov/41179310","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52457,"output_tokens":10075,"usd":0.154248,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20672,"output_tokens":5150,"usd":0.116055,"stage2_stop_reason":"end_turn"},"total_usd":0.270303,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"RALDH3 (ALDH1A3) functions as a retinaldehyde dehydrogenase, catalyzing the oxidation of retinaldehyde to retinoic acid, and is expressed specifically in the ventral retina, otic vesicle, and olfactory pit during mouse embryonic development, with expression pattern distinct from RALDH1 and RALDH2.\",\n      \"method\": \"cDNA cloning, in situ hybridization, expression pattern analysis in mouse embryos\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic activity (retinaldehyde dehydrogenase) established by cloning and expression; replicated independently in two papers (PMID 11025231, PMID 11044606) with orthogonal methods including enzymatic activity assays\",\n      \"pmids\": [\"11025231\", \"11044606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ALDH6 (ALDH1A3) encodes a 512 amino acid aldehyde dehydrogenase isozyme expressed highly in salivary gland, stomach, and kidney, and maps to chromosome 15q26; the gene spans ~37 kb with 13 exons.\",\n      \"method\": \"cDNA cloning, Northern blot analysis, fluorescence in situ hybridization for chromosomal localization\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct molecular cloning with enzymatic classification, chromosomal mapping, and expression profiling; foundational characterization paper\",\n      \"pmids\": [\"7698756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"RALDH-3 (ALDH1A3) is the chick ortholog of human ALDH6, is specifically expressed in the ventral retina, and shows enzymatic activity to produce retinoic acid from retinaldehyde; its expression in the ventral retina is dependent on Pax6 transcription factor.\",\n      \"method\": \"Restriction landmark cDNA scanning, enzymatic activity assay, in situ hybridization, Pax6 mutant analysis\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzymatic activity directly demonstrated in vitro; Pax6 dependency shown in mutant embryos; replicated across labs\",\n      \"pmids\": [\"11044606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Raldh3 expression in the subventricular zone of the lateral ganglionic eminence (LGE) is required for retinoic acid signaling in the ventral forebrain; Raldh3 null mice lack RA signaling in the ventral forebrain and show essentially eliminated dopamine receptor D2 expression in the developing nucleus accumbens.\",\n      \"method\": \"Genetic epistasis using Raldh2/Raldh3 single and double null mouse mutants, RA signaling reporter assays, in situ hybridization\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function genetics with defined molecular and cellular phenotype; double-knockout epistasis; multiple orthogonal readouts\",\n      \"pmids\": [\"17207476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ALDH1A3 is an androgen-responsive gene in prostate cancer LNCaP cells: dihydrotestosterone (DHT) induces a ~4-fold increase in ALDH1A3 mRNA via the androgen receptor (AR) nuclear-translocation cascade, and DHT-upregulated ALDH1A3 increases retinaldehyde-dependent NAD+ reduction ~8-fold, leading to increased retinoic acid biosynthesis.\",\n      \"method\": \"qRT-PCR, siRNA knockdown of AR, pharmacologic inhibition of AR (bicalutamide) and kinases (PD98059, PP1), enzymatic activity assay (retinaldehyde-dependent NAD+ reduction), CYP26A1 mRNA induction\",\n      \"journal\": \"Experimental biology and medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (siRNA, pharmacologic inhibitors, enzymatic assay) in single lab demonstrating AR-dependent transcriptional regulation and functional enzymatic consequence\",\n      \"pmids\": [\"17526768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ALDH activity of breast cancer stem cells is primarily attributable to ALDH1A3 expression, not ALDH1A1; shRNA knockdown of ALDH1A3 (but not other isoforms) uniformly reduces ALDH activity in breast cancer cells.\",\n      \"method\": \"Genome microarray expression, immunofluorescence, qPCR, shRNA knockdown, Aldefluor assay\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isoform-specific shRNA knockdown with direct functional readout (ALDH activity), replicated across multiple cell lines and patient tumor CSCs\",\n      \"pmids\": [\"21280157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Loss-of-function mutations in ALDH1A3 cause autosomal recessive anophthalmia/microphthalmia in humans; missense mutations reduce accumulation of the enzyme, likely leading to altered retinoic acid synthesis during eye development.\",\n      \"method\": \"Homozygosity mapping, exome sequencing, Sanger sequencing, transitory expression of mutant ALDH1A3 ORFs to assess protein accumulation\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetics with functional validation of mutant protein expression; replicated in multiple independent families and studies (PMID 23312594, 23591992, 23646827, 23881059)\",\n      \"pmids\": [\"23312594\", \"23591992\", \"23646827\", \"23881059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Morpholino-mediated knockdown of aldh1a3 in zebrafish causes significant reduction in eye size and aberrant axonal projections to the tectum, confirming a conserved role in eye development.\",\n      \"method\": \"Antisense morpholino injection in Danio rerio, eye size measurement, axonal projection analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean loss-of-function in animal model with defined phenotype (eye size, axonal projections); single lab, single model organism\",\n      \"pmids\": [\"23591992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A missense mutation (p.Val71Met) in ALDH1A3 associated with isolated anophthalmia/microphthalmia showed no change in enzymatic activity in vitro, suggesting the pathogenic mechanism may involve altered protein stability or localization rather than catalytic impairment.\",\n      \"method\": \"In vitro enzymatic activity assay of wild-type vs. mutant ALDH1A3 protein\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro enzymatic assay; single lab, negative finding (no activity change) that is mechanistically informative\",\n      \"pmids\": [\"23881059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A pSTAT3(tyr705)-NFkB(p65) complex represses DDIT3 mRNA, which ensures high CEBPβ-dependent ALDH1A3 promoter activity; inhibition of this STAT3-NFkB axis allows DDIT3 expression, which forms a DDIT3-CEBPβ complex that reduces CEBPβ occupancy at the ALDH1A3 promoter, thereby reducing ALDH1A3 expression in chemoresistant mesothelioma cells.\",\n      \"method\": \"RNAi, promoter activity assays, ChIP, co-immunoprecipitation, in vivo xenograft models\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter occupancy by ChIP, co-IP of STAT3-NFkB complex, and RNAi loss-of-function; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25868979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXD1 transcription factor directly regulates the transcriptional activity of ALDH1A3 in mesenchymal glioma stem cells (MES GSC); shRNA attenuation of FOXD1 ablates ALDH1A3-dependent clonogenicity in vitro and in vivo.\",\n      \"method\": \"shRNA knockdown, in vitro clonogenicity assays, in vivo xenograft models, RNAi in Drosophila brain tumor model (genetic conservation), luciferase reporter for ALDH1A3 transcription\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis demonstrated by shRNA knockdown of both genes with clonogenicity readout; FOXD1 regulation of ALDH1A3 transcription shown; single lab\",\n      \"pmids\": [\"27569208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sam68 (KHDRBS1) RNA-binding protein binds to an intronic polyadenylation site in Aldh1a3 pre-mRNA, preventing premature transcript termination and enabling expression of full-length functional ALDH1A3 enzyme; loss of Sam68 reduces ALDH1A3 expression and activity, leading to reduced glycolysis and clonogenicity in neural progenitor cells.\",\n      \"method\": \"Khdrbs1 knockout mouse, pre-mRNA 3'-end processing assay, clonogenicity, glycolysis assays, RNA-binding protein binding experiments\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with mechanistic dissection of RNA processing (intronic polyadenylation site binding), multiple functional readouts (glycolysis, clonogenicity, NPC pool), single rigorous study with orthogonal methods\",\n      \"pmids\": [\"27845622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ALDH1A3 regulates transcriptional expression of tissue transglutaminase (tTG) via its retinoic acid (RA) biosynthesis activity in mesenchymal glioma stem cells; enzymatic activity of ALDH1A3 and its product RA are necessary for tTG expression, and ectopic ALDH1A3 expression in proneural GSCs is sufficient to induce tTG.\",\n      \"method\": \"shRNA/siRNA knockdown, ectopic ALDH1A3 expression, RA supplementation rescue experiments, inhibitor treatment\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with RA rescue; enzymatic activity linked to downstream effector (tTG); single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"28423611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CHD7 (an ATP-dependent chromatin remodeler) directly binds and represses the Aldh1a3 gene in the inner ear; loss of Aldh1a3 partially rescues Chd7 mutant mouse inner ear defects, placing CHD7 upstream of ALDH1A3 in a common genetic pathway regulating inner ear development.\",\n      \"method\": \"CHD7 chromatin binding assays, Chd7/Aldh1a3 double mutant genetic epistasis in mice, inner ear phenotypic rescue analysis\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct CHD7 binding to Aldh1a3 gene demonstrated; double-mutant genetic rescue epistasis in mouse; mechanistically rigorous single study\",\n      \"pmids\": [\"29467333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ALDH1A3 protein is regulated post-translationally by autophagy: ALDH1A3 physically interacts with p62 (sequestosome 1/SQSTM1), an autophagosome adaptor protein, and temozolomide-induced autophagy leads to ALDH1A3 protein downregulation without affecting mRNA levels.\",\n      \"method\": \"Co-immunoprecipitation (ALDH1A3-p62 interaction), Western blot, qPCR (mRNA vs protein level comparison), autophagy induction/inhibition\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP demonstrating physical interaction with p62; mRNA vs protein discordance supporting post-transcriptional regulation; single lab\",\n      \"pmids\": [\"29306018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"USP9X (ubiquitin-specific protease 9X) acts as a bona fide deubiquitinase of ALDH1A3 in mesenchymal glioblastoma stem cells: USP9X interacts with ALDH1A3, depolyubiquitylates it, and stabilizes the protein; depletion of USP9X downregulates ALDH1A3, causing loss of self-renewal and tumorigenicity that can be rescued by ectopic ALDH1A3 expression.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays (depolyubiquitylation), USP9X depletion + ALDH1A3 rescue experiments, orthotopic xenograft models, USP9X inhibitor (WP1130) treatment\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, direct deubiquitination assay, epistatic rescue experiment, in vivo validation; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"30958800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ALDH1A3 regulates expression of lncRNA NRAD1 through retinoic acid signaling; NRAD1 is primarily nuclear-localized and functions downstream of ALDH1A3 to regulate gene expression via chromatin interactions, mediating part of ALDH1A3's effects on cancer stem cell gene expression.\",\n      \"method\": \"Cellular fractionation (nuclear localization), transcriptome profiling, ChIRP-seq (chromatin isolation by RNA purification + sequencing), antisense oligonucleotide knockdown, ALDH1A3 knockdown with NRAD1 measurement\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular fractionation, ChIRP-seq for chromatin interactions, RA rescue experiments; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"31197235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ALDH1A3 promotes vascular smooth muscle cell (VSMC) proliferation at least partially through upregulation of matricellular proteins TNC1 and ESM1, which activate AKT/mTOR and/or MEK/ERK pathways; ALDH1A3 silencing abolishes PDGF(BB)-stimulated VSMC total ALDH activity and proliferation.\",\n      \"method\": \"siRNA knockdown, ALDH activity assay, proliferation assay, pathway inhibition, in vivo angioplasty rat carotid model with ALDH inhibitor disulfiram\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with defined cellular phenotype (proliferation), downstream effector identification (TNC1/ESM1), in vivo validation; single lab\",\n      \"pmids\": [\"31513972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Raldh3 (ALDH1A3) overexpression reduces insulin secretion from β-cells (MIN6) and increases glucagon secretion from α-cells (αTC1 clone 9); knockdown of Raldh3 decreases glucagon secretion; 13-cis retinoic acid (the product of Raldh3 catalysis of 13-cis retinal) reduces cell viability specifically in MIN6 and αTC1 cells.\",\n      \"method\": \"Overexpression, siRNA knockdown, insulin/glucagon secretion assays, 13-cis retinoic acid treatment, cell viability assays in multiple cell lines\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with direct secretion readouts; product (13-cis RA) mechanistically linked to cell viability; single lab\",\n      \"pmids\": [\"20833146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Nuclear ALDH1A3 in pulmonary arterial smooth muscle cells (PASMC) converts acetaldehyde to acetate, producing acetyl-CoA that acetylates histone H3K27 at active enhancers; this enables KAT2B acetyltransferase-mediated chromatin modification at NFYA binding sites and NFY-mediated transcription of cell cycle and metabolic genes required for SMC proliferation and glycolysis. Mice with SMC-specific Aldh1a3 deletion did not develop hypoxia-induced pulmonary arterial muscularization or pulmonary hypertension.\",\n      \"method\": \"RNA sequencing, nuclear fractionation and localization, metabolic flux analysis (acetaldehyde→acetate→acetyl-CoA), H3K27 acetylation ChIP, KAT2B acetyltransferase assays, NFYA ChIP, SMC-specific Aldh1a3 knockout mouse (hypoxia model), siRNA knockdown\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — nuclear metabolic-epigenetic mechanism with enzymatic substrate identification, ChIP for histone modification, acetyltransferase assay, tissue-specific KO mouse with in vivo phenotype; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"33764154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ALDH1A3 stabilizes PKM2 by reducing its ubiquitination, thereby promoting aerobic glycolysis (Warburg effect) in colorectal cancer cells; ALDH1A3 and PKM2 interact as identified by co-immunoprecipitation followed by mass spectrometry.\",\n      \"method\": \"Co-immunoprecipitation with mass spectrometry (PKM2 identification), ubiquitination assay (PKM2 stabilization), glycolysis assays, siRNA knockdown\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP/MS for interaction identification, ubiquitination assay for mechanism; single lab\",\n      \"pmids\": [\"33419984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A selective, competitive inhibitor (MCI-INI-3) targeting the active site of human ALDH1A3 was developed using the crystal structure of ALDH1A3; mass spectrometry-based cellular thermal shift analysis confirmed ALDH1A3 as the primary cellular binding protein; MCI-INI-3 inhibits retinoic acid biosynthesis comparably to ALDH1A3 knockout.\",\n      \"method\": \"Crystal structure of human ALDH1A3, in silico modeling, in vitro competitive inhibition assay, mass spectrometry-based cellular thermal shift assay (CETSA), ALDH1A3 knockout comparison\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with active-site inhibitor design, in vitro competitive inhibition assay, cellular target engagement by CETSA, knockout comparison; multiple orthogonal methods\",\n      \"pmids\": [\"34934174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ALDH1A3 is the key isoform responsible for ALDH activity in cardiac atrial appendage progenitor cells; ALDH1A3 knockdown (but not ALDH1A1, ALDH1A2, ALDH2, ALDH4A1, or ALDH8A1) decreases ALDH activity and cell proliferation, while ALDH1A3 overexpression increases proliferation in ALDHlo cells.\",\n      \"method\": \"siRNA knockdown of individual ALDH isoforms, Aldefluor activity assay, retroviral overexpression, cell proliferation assay\",\n      \"journal\": \"Frontiers in cardiovascular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific siRNA with gain- and loss-of-function; direct functional readout (ALDH activity, proliferation); single lab\",\n      \"pmids\": [\"30087899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Genetic or pharmacological inhibition of ALDH1A3 in diabetic mice lowers glycemia and increases insulin secretion; lineage tracing shows that ALDH1A3-positive β-cells (dedifferentiated) can be reconverted to functional mature β-cells upon ALDH1A3 inhibition, and ALDH1A3 inhibition reactivates differentiation and regeneration pathways.\",\n      \"method\": \"Somatic ALDH1A3 ablation (genetic), lineage tracing, selective pharmacological ALDH1A3 inhibitor treatment, glycemia measurement, insulin secretion assay, gene expression profiling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic ablation and pharmacological inhibition with defined in vivo metabolic phenotypes; lineage tracing; multiple orthogonal approaches in single study\",\n      \"pmids\": [\"36732513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALDH1A3 interacts with PKM2 and enhances PKM2 tetramerization, promoting lactate accumulation in glioblastoma stem cells; accumulated lactate leads to lactylation of XRCC1 at K247, which increases XRCC1 affinity for importin α, enabling nuclear transposition of XRCC1 and enhanced DNA repair, thereby conferring chemoradiotherapy resistance.\",\n      \"method\": \"Co-immunoprecipitation (ALDH1A3-PKM2 interaction), lactylated proteome scanning by mass spectrometry, XRCC1-importin α binding assay, nuclear fractionation, high-throughput small molecule screening (D34-919 disrupts ALDH1A3-PKM2 interaction), in vitro and in vivo treatment\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — Co-IP for protein-protein interaction, MS-based proteome scan, site-specific lactylation (K247) identified, importin α binding assay, nuclear localization, in vivo validation; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"39111285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALDH1A3 forms an enzymatic partnership with ACSS2 (acetyl-CoA synthetase 2) in the nucleus of melanoma cells, coupling glucose metabolic flux with acetyl-histone H3 modification of neural crest lineage and glucose metabolism genes; acetaldehyde serves as a metabolite source for acetyl-histone H3 modification in an ALDH1A3-dependent manner.\",\n      \"method\": \"Nuclear fractionation, ChIP for acetyl-H3 marks, metabolic flux analysis, ALDH1A3 inhibition/genetic manipulation, zebrafish melanoma residual disease model, ALDH1 suicide inhibitor (nifuroxazide)\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — nuclear ALDH1A3-ACSS2 partnership established with ChIP, metabolic flux linking acetaldehyde to acetyl-H3, in vivo zebrafish model; multiple orthogonal methods\",\n      \"pmids\": [\"38963759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALDH1A3 regulates the balance between two distinct breast cancer stem cell populations (ALDH+ and CD24-CD44+) via retinoic acid signaling-mediated gene expression; while ALDH1A3 increases ALDH+ cells, it inversely suppresses CD24-CD44+ cells. ALDH1A3 also increases oxidative phosphorylation and decreases glycolysis and ROS.\",\n      \"method\": \"ALDH1A3 knockdown/overexpression, Aldefluor assay, flow cytometry (CD44/CD24), metabolic assays (OXPHOS, glycolysis, ROS), retinoic acid signaling pathway inhibition, 2-DG (glycolysis inhibitor) rescue, xenograft tumor models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with multiple metabolic and cellular readouts; retinoic acid signaling mechanistically linked; single lab\",\n      \"pmids\": [\"39251846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ALDH1A3 promotes invasion and metastasis of triple-negative breast cancer by regulating the plasminogen activation pathway: ALDH1A3 increases levels and activity of tPA and uPA, leading to increased plasmin activity; this invasion is plasminogen-dependent, and the ALDH1A3 product all-trans-retinoic acid similarly increases tPA and plasmin activity.\",\n      \"method\": \"ALDH1A3 knockdown/overexpression, tPA/uPA activity assays, plasmin activity assay, plasminogen-dependent invasion assays, retinoic acid treatment, tPA knockdown in vivo (lymph node metastasis model)\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity assays (plasmin, tPA, uPA), RA product mechanistically linked, in vivo metastasis model; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"37753740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ALDH1A3 knockdown in glioblastoma reduces tumor cell invasion in vitro; ALDH1A3 is associated with mesenchymal transformation and drives changes in extracellular matrix organization and cell adhesion gene expression.\",\n      \"method\": \"siRNA/shRNA knockdown, Transwell invasion assay, Aldefluor flow cytometry, transcriptome analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — loss-of-function with direct invasion assay readout; single lab, single method for invasion\",\n      \"pmids\": [\"30538217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ALDH1A3 promotes pancreatic cancer metastasis via metabolic regulation: ALDH1A3 activates PI3K/AKT/mTOR signaling and downstream PPARγ, which increases HK2 (hexokinase 2) expression and enhances glycolysis; pharmacological inhibition of PPARγ in ALDH1A3-positive cells impairs glycolytic gene expression and PI3K/AKT/mTOR activity.\",\n      \"method\": \"ALDH1A3 shRNA knockdown, overexpression, RNA-seq, glycolysis assays (glucose uptake, lactate, ATP), PPARγ inhibitor treatment, in vitro metastasis assays, in vivo metastasis models\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq pathway identification, pharmacologic epistasis (PPARγ inhibitor rescue), metabolic assays; single lab\",\n      \"pmids\": [\"32612951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ALDH1A3 depletion affects mTOR cell survival pathway gene expression, coinciding with decreased activating phosphorylation of S6 kinase, placing ALDH1A3 upstream of mTOR signaling in drug-tolerant gastric cancer persister cells.\",\n      \"method\": \"RNA interference, gene expression analysis, Western blot (S6 kinase phosphorylation), mTOR inhibitor (temsirolimus) treatment, single-cell analysis, xenograft tumor models\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (ALDH1A3 depletion → mTOR pathway), signaling pathway validation by Western blot, pharmacologic confirmation; single lab\",\n      \"pmids\": [\"31960523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-187 directly targets ALDH1A3 in prostate cancer cells; re-introduction of miR-187 in PC-3 cells downregulates ALDH1A3 protein and mRNA levels, identified by 2D-DIGE proteomics and validated by Western blot and qRT-PCR.\",\n      \"method\": \"2D-DIGE proteomics, MALDI-TOF MS, LC-MS/MS, Western blot, qRT-PCR, miR-187 precursor transfection\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic identification with direct Western blot validation; miRNA-target relationship established; single lab, multiple methods\",\n      \"pmids\": [\"25969992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PPARγ directly binds to a PPARγ response element (binding site 2) in the ALDH1A3 promoter and suppresses ALDH1A3 mRNA and protein expression upon ligand activation; ALDH1A3 suppression by PPARγ leads to accumulation of 4-HNE (lipid peroxidation marker) in PPARγ-positive lung cancer cells.\",\n      \"method\": \"NUBIscan in silico binding site prediction, ChIP assay (PPARγ binding to ALDH1A3 promoter BS2), QPCR, Western blot, PPARγ activator (TZD) treatment, 4-HNE Western blot\",\n      \"journal\": \"Journal of receptor and signal transduction research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirmed direct PPARγ binding to ALDH1A3 promoter; functional consequence shown (4-HNE accumulation); single lab\",\n      \"pmids\": [\"29873276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALDH1A3 contributes to tumorigenesis in high-grade serous ovarian cancer by increasing acetyl-CoA production, which leads to H3K27 acetylation at the PITX1 promoter and transcriptional activation of PITX1; ALDH1A3 knockdown reduces H3K27ac levels and PITX1 expression. ALDH1A3 expression is transcriptionally activated by HIF-1α.\",\n      \"method\": \"RNA-seq, siRNA knockdown, dual-luciferase reporter assay (HIF-1α→ALDH1A3 promoter), ChIP assay (H3K27ac at PITX1 promoter), exogenous acetate treatment (NaOAc), HDAC inhibitor (Pracinostat), HIF-1α inhibitor (KC7F2)\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for H3K27ac at PITX1 promoter, acetate rescue experiment, HIF-1α reporter assay; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"38211842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network; ALDH1A3 affects acetylation of histone H3, mediating AP-1 activity (particularly FOS family members) and activating MAPK and TNF signaling; RUNX2 knockdown disrupted MAPK signaling and reduced tumor growth.\",\n      \"method\": \"Chromatin profiling (H3 acetylation), functional interaction studies (FAM3C, MCC, PMEPA1, IRS2), RUNX2 knockdown, MAPK pathway analysis, xenograft tumor models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromatin profiling linking ALDH1A3 to histone acetylation and AP-1 activity; RUNX2 epistasis; single lab\",\n      \"pmids\": [\"40781158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ALDH1A3 knockdown in prostate cancer promotes cellular senescence-like phenotype while reducing SASP pro-inflammatory factor secretion via inhibition of the cGAS-STING pathway.\",\n      \"method\": \"ALDH1A3 siRNA knockdown, senescence assays, SASP factor measurement, cGAS-STING pathway analysis, radiotherapy in vitro model\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pathway placement by knockdown with limited mechanistic validation of cGAS-STING link\",\n      \"pmids\": [\"40227735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Compound heterozygous mutations in ALDH1A3 (c.287G>A and c.709G>A) cause anophthalmia; in vitro expression analysis showed that mutated alleles are associated with decreased protein production and impaired tetrameric protein formation.\",\n      \"method\": \"Exome sequencing, Sanger sequencing, in vitro expression analysis, native protein gel/tetrameric protein formation assay\",\n      \"journal\": \"Genetics and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — in vitro protein expression and tetramer formation assay; establishes protein quaternary structure requirement; single study\",\n      \"pmids\": [\"28590501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ALDH1A3 and ALDH1A1 paralogues are both pivotal for myogenic differentiation of skeletal muscle satellite cells (C2C12 myoblasts): CRISPR/Cas9 single-paralogue knockout impairs differentiation, and retinoic acid (RA) analogue TTNPB restores differentiation in knockout cells. ALDH1-paralogue knockout also impairs autophagic flux (p62 formation and LC3B-I to LC3B-II conversion).\",\n      \"method\": \"CRISPR/Cas9 knockout, recombinant ALDH1A3 re-expression rescue, RA analogue (TTNPB) treatment, RA receptor antagonist (AGN 193109) treatment, autophagy flux assays (p62, LC3B Western blot)\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with genetic rescue by re-expression, RA pathway epistasis, autophagy flux assay; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"37904003\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ALDH1A3 is a retinaldehyde dehydrogenase (NAD+-dependent) that oxidizes retinaldehyde to retinoic acid, and in the nucleus also converts acetaldehyde to acetate, generating acetyl-CoA that drives H3K27 acetylation at enhancers/promoters to epigenetically regulate cell cycle, metabolic, and lineage genes; it stabilizes PKM2 through direct protein interaction to promote glycolysis and lactate-mediated XRCC1 lactylation; it is post-translationally regulated by USP9X-mediated deubiquitination (stabilizing it) and by autophagy/p62-mediated degradation; transcriptionally it is controlled by FOXD1, CEBPβ (via STAT3-NFkB-DDIT3 axis), HIF-1α, androgen receptor, and CHD7; upstream RNA-level regulation occurs via Sam68-mediated prevention of intronic polyadenylation; the enzyme is critical for retinoic acid-dependent developmental patterning of the eye, inner ear, forebrain, and olfactory system, and its loss-of-function causes human autosomal recessive anophthalmia/microphthalmia.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ALDH1A3 is an NAD+-dependent retinaldehyde dehydrogenase that oxidizes retinaldehyde to retinoic acid and, through this activity, drives retinoic acid-dependent developmental patterning of the eye, inner ear, and ventral forebrain [#0, #2, #3]. It is expressed selectively in ventral retina, otic vesicle, and olfactory pit during embryogenesis, where its retinoic acid output is required for ventral forebrain RA signaling and dopamine receptor D2 expression [#0, #3]. Loss-of-function mutations in ALDH1A3 cause human autosomal recessive anophthalmia/microphthalmia, with pathogenic alleles acting predominantly through reduced protein accumulation and impaired tetramer formation rather than loss of intrinsic catalysis [#6, #36, #8]; the developmental requirement is conserved, as aldh1a3 knockdown reduces eye size in zebrafish [#7]. Beyond its developmental role, ALDH1A3 is the dominant ALDH isoform underlying ALDH activity in breast cancer, glioma, and cardiac progenitor stem-cell populations and sustains their self-renewal and tumorigenicity [#5, #22]. A nuclear, non-canonical function couples metabolism to chromatin: nuclear ALDH1A3 oxidizes acetaldehyde to acetate, generating acetyl-CoA — in partnership with the acetyl-CoA synthetase ACSS2 — that fuels H3K27/histone H3 acetylation at enhancers and promoters of cell-cycle, metabolic, and lineage genes, a mechanism required for smooth muscle proliferation in pulmonary hypertension, melanoma neural-crest gene programs, and ovarian and pancreatic cancer transcriptional networks [#19, #25, #33, #34]. ALDH1A3 also acts independently of catalysis through direct protein interactions, binding and stabilizing PKM2 to promote aerobic glycolysis and, via enhanced PKM2 tetramerization and lactate production, driving lactylation-dependent nuclear import of XRCC1 and DNA-repair-mediated therapy resistance [#20, #24]. Its abundance is set post-translationally by USP9X-mediated deubiquitination that stabilizes the protein and by p62/autophagy-mediated degradation [#15, #14], transcriptionally by FOXD1, CEBP\\u03b2 (downstream of a STAT3-NF\\u03baB-DDIT3 axis), HIF-1\\u03b1, PPAR\\u03b3, the androgen receptor, and the chromatin remodeler CHD7 [#10, #9, #33, #32, #4, #13], and at the RNA level by Sam68-dependent suppression of intronic polyadenylation that permits full-length transcript expression [#11]. A crystal structure of human ALDH1A3 has enabled active-site-directed competitive inhibitors that phenocopy genetic loss [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing ALDH1A3 as a discrete aldehyde dehydrogenase isozyme with defined gene structure and tissue distribution provided the molecular foundation for all subsequent functional study.\",\n      \"evidence\": \"cDNA cloning, Northern blot, and FISH chromosomal mapping\",\n      \"pmids\": [\"7698756\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the physiological substrate or enzymatic specificity\", \"No developmental or disease role assigned\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identifying retinaldehyde as the substrate and retinoic acid as the product, with spatially restricted embryonic expression, defined ALDH1A3 as a region-specific generator of the morphogen retinoic acid.\",\n      \"evidence\": \"cDNA cloning, in vitro enzymatic activity assay, in situ hybridization in mouse and chick embryos, Pax6 mutant analysis\",\n      \"pmids\": [\"11025231\", \"11044606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish in vivo developmental requirement\", \"Upstream regulators beyond Pax6 unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Loss-of-function genetics demonstrated that ALDH1A3-derived retinoic acid is required for ventral forebrain patterning, moving the gene from a marker to a causal developmental signal.\",\n      \"evidence\": \"Raldh2/Raldh3 single and double null mouse epistasis with RA reporter and in situ readouts\",\n      \"pmids\": [\"17207476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional targets of RA in forebrain not fully mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Human genetics and zebrafish modeling established ALDH1A3 as a cause of autosomal recessive anophthalmia/microphthalmia, linking enzyme deficiency to congenital eye malformation.\",\n      \"evidence\": \"Homozygosity mapping, exome sequencing, mutant protein expression assays, in vitro enzymatic assay, zebrafish morpholino knockdown\",\n      \"pmids\": [\"23312594\", \"23591992\", \"23646827\", \"23881059\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Not all mutations impair catalysis (p.Val71Met retained activity), implicating stability/folding\", \"Exact developmental window of pathogenesis unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Native gel analysis of mutant alleles showed that pathogenic mutations impair tetrameric assembly and protein production, clarifying that protein stability, not always catalysis, underlies disease.\",\n      \"evidence\": \"In vitro expression and tetramer formation assays of mutant alleles\",\n      \"pmids\": [\"28590501\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quaternary structure requirement not tested in vivo\", \"Folding chaperone or degradation pathway for unstable mutants not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Isoform-specific knockdown revealed ALDH1A3 as the principal contributor to the ALDH activity that marks cancer stem cells, recasting the enzyme as a stem-cell functional determinant.\",\n      \"evidence\": \"Genome microarray, shRNA knockdown, Aldefluor assay across breast cancer cell lines and patient CSCs\",\n      \"pmids\": [\"21280157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking ALDH activity to stemness not defined at this stage\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Multiple regulatory inputs were mapped — transcriptional control by FOXD1 and a STAT3-NF\\u03baB-DDIT3-CEBP\\u03b2 axis, and RNA-level control by Sam68-dependent suppression of intronic polyadenylation — explaining how ALDH1A3 levels are tuned in stem and cancer cells.\",\n      \"evidence\": \"shRNA/RNAi, promoter and luciferase reporter assays, ChIP, co-IP, Khdrbs1 knockout mouse with pre-mRNA 3'-processing assays\",\n      \"pmids\": [\"27569208\", \"25868979\", \"27845622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Combinatorial integration of these regulators in a given tissue unresolved\", \"Sam68-ALDH1A3 axis tested mainly in neural progenitors\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Post-translational control was established through p62/autophagy-mediated degradation and CHD7-mediated transcriptional repression, expanding the regulatory layers governing ALDH1A3 abundance.\",\n      \"evidence\": \"Co-IP (ALDH1A3-p62), mRNA-vs-protein comparison, autophagy modulation; CHD7 chromatin binding and Chd7/Aldh1a3 double-mutant mouse rescue\",\n      \"pmids\": [\"29306018\", \"29467333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase upstream of autophagic turnover not identified\", \"Direct vs indirect CHD7 repression mechanism only partly resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"USP9X was identified as a deubiquitinase that stabilizes ALDH1A3, establishing the ubiquitin-proteasome counterbalance to its degradation and a node sustaining glioblastoma stem-cell self-renewal.\",\n      \"evidence\": \"Reciprocal co-IP, depolyubiquitylation assays, USP9X depletion with ALDH1A3 rescue, orthotopic xenografts, USP9X inhibitor\",\n      \"pmids\": [\"30958800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The opposing E3 ubiquitin ligase remains unidentified\", \"Whether USP9X regulation is tissue-restricted unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The discovery that nuclear ALDH1A3 converts acetaldehyde to acetate to generate acetyl-CoA for histone H3K27 acetylation revealed a moonlighting metabolic-epigenetic function distinct from retinoic acid signaling.\",\n      \"evidence\": \"Nuclear fractionation, metabolic flux analysis, H3K27ac and NFYA ChIP, KAT2B acetyltransferase assay, SMC-specific Aldh1a3 knockout mouse in hypoxia\",\n      \"pmids\": [\"33764154\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of nuclear vs cytoplasmic ALDH1A3 partitioning not defined\", \"Generality across cell types established only later\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Structure-guided inhibitor development produced a selective active-site competitive inhibitor that phenocopies ALDH1A3 knockout, providing a chemical tool and validating the active site as a target.\",\n      \"evidence\": \"Human ALDH1A3 crystal structure, in silico modeling, competitive inhibition assay, CETSA target engagement, knockout comparison\",\n      \"pmids\": [\"34934174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitor does not address non-catalytic protein-interaction functions\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of a direct ALDH1A3-PKM2 interaction that stabilizes PKM2 and promotes aerobic glycolysis revealed a non-enzymatic, scaffolding role in tumor metabolism.\",\n      \"evidence\": \"Co-IP/mass spectrometry, PKM2 ubiquitination assay, glycolysis assays, siRNA knockdown in colorectal cancer cells\",\n      \"pmids\": [\"33419984\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction interface and whether catalysis is required not defined\", \"Single cancer context\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mechanistic dissection extended the nuclear acetyl-CoA/ACSS2 axis to melanoma lineage and ovarian/pancreatic cancer transcriptional networks, and connected the PKM2 interaction to lactate-driven XRCC1 lactylation and DNA-repair-mediated therapy resistance.\",\n      \"evidence\": \"Nuclear fractionation, ChIP for acetyl-H3/H3K27ac, metabolic flux, lactylated-proteome MS, XRCC1-importin\\u03b1 binding, zebrafish melanoma model, small-molecule disruptors\",\n      \"pmids\": [\"38963759\", \"39111285\", \"38211842\", \"40781158\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of nuclear vs cytosolic acetyl-CoA pools unresolved\", \"How a single enzyme coordinates metabolic and chromatin functions in vivo not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ALDH1A3 was implicated in beta-cell dedifferentiation, with inhibition reconverting dedifferentiated beta-cells to functional mature cells, revealing a role in cellular identity beyond cancer and development.\",\n      \"evidence\": \"Genetic ablation, lineage tracing, selective pharmacological inhibition, glycemia and insulin secretion assays in diabetic mice\",\n      \"pmids\": [\"36732513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the metabolic-epigenetic or RA function drives dedifferentiation not separated\", \"Mechanism of reversal incompletely defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ALDH1A3's three modes — retinoic acid synthesis, nuclear acetyl-CoA generation for histone acetylation, and catalysis-independent protein stabilization of PKM2 — are partitioned and coordinated within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No determinant identified that controls nuclear vs cytoplasmic localization\", \"Relative weighting of enzymatic vs scaffolding functions across tissues unknown\", \"No integrated structure-function model linking tetramerization, catalysis, and protein interactions\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 2, 4, 19, 21, 25]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [19, 25]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [20, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [19, 24, 25]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 3, 6, 7, 13]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [19, 20, 24, 25, 29]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [19, 25, 33, 34]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [6, 36]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PKM2\", \"USP9X\", \"SQSTM1\", \"ACSS2\", \"KHDRBS1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}